HDFN,Hemolytic Disease of the Fetus and Newborn)
Conditions
Interventions
Blood transfusion group (weak D15, weak D960A, weak D25, weak D72, and weak D33 blood types):Transfusion of ABO-identical, RhD-positive blood that is cross-matching compatible.
Sponsors
Guabgzhou First People‘s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Adult male weak D patients aged 18–80 years, or non-reproductive female weak D patients aged 49–80 years; 2.Patients who are clinically indicated for red blood cell transfusion in accordance with the Medical, Surgical, and Trauma Transfusion Guidelines of the "Technical Specifications for Clinical Blood Transfusion," taking into account the patient's severity of anemia, cardiopulmonary compensation, metabolic rate, age, and other factors. 3.Voluntary signing of the informed consent form for the clinical trial transfusion therapy before the trial. The patient and/or their legal representative must have the capacity to fully understand the trial content, procedures, and possible adverse reactions, and be able to comply with the protocol-specified visits and examinations.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of severe transfusion adverse reactions; 2.Patients requiring emergency blood transfusion for acute blood loss due to trauma or other causes; 3.Patients with impaired consciousness or severe mental illness; 4.Other patients deemed by the investigator to be unsuitable for participation in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-D alloimmunization rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemoglobin concentration and hematocrit ;Rate of autoantibody mimicking anti-D; | — |
Countries
China
Contacts
Public ContactYongshui Fu
Guabgzhou First People‘s Hospital
Outcome results
None listed